Loading...

NOXXON Pharma

BST:0N6
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0N6
BST
€14M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
0N6 Share Price and Events
7 Day Returns
0%
BST:0N6
-2.1%
DE Biotechs
-3.8%
DE Market
1 Year Returns
-
BST:0N6
-7.8%
DE Biotechs
-18.5%
DE Market
0N6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NOXXON Pharma (0N6) 0% 0% 0.8% - - -
DE Biotechs -2.1% -4.9% -11.6% -7.8% 43.8% -0.7%
DE Market -3.8% -6.7% -10.2% -18.5% -2% 7.9%
1 Year Return vs Industry and Market
  • No trading data on 0N6.
  • No trading data on 0N6.
Price Volatility
0N6
Industry
5yr Volatility vs Market

0N6 Value

 Is NOXXON Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether NOXXON Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NOXXON Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NOXXON Pharma. This is due to cash flow or dividend data being unavailable. The share price is €2.52.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NOXXON Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NOXXON Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:0N6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-3.12
ENXTPA:ALNOX Share Price ** ENXTPA (2018-09-10) in EUR €1.51
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 25.6x
Germany Market PE Ratio Median Figure of 413 Publicly-Listed Companies 16.97x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NOXXON Pharma.

BST:0N6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALNOX Share Price ÷ EPS (both in EUR)

= 1.51 ÷ -3.12

-0.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NOXXON Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NOXXON Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NOXXON Pharma's expected growth come at a high price?
Raw Data
BST:0N6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.18x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.27x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NOXXON Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NOXXON Pharma's assets?
Raw Data
BST:0N6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €-1.82
ENXTPA:ALNOX Share Price * ENXTPA (2018-09-10) in EUR €1.51
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.43x
Germany Market PB Ratio Median Figure of 556 Publicly-Listed Companies 1.76x
BST:0N6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALNOX Share Price ÷ Book Value per Share (both in EUR)

= 1.51 ÷ -1.82

-0.83x

* Primary Listing of NOXXON Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NOXXON Pharma has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 0N6’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through NOXXON Pharma's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess NOXXON Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NOXXON Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0N6 Future Performance

 How is NOXXON Pharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
212.8%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is NOXXON Pharma expected to grow at an attractive rate?
  • Unable to compare NOXXON Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NOXXON Pharma's earnings growth to the Germany market average as no estimate data is available.
  • NOXXON Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:0N6 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:0N6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 212.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 48.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:0N6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:0N6 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 26 7 1
2018-12-31 0 -6 1
BST:0N6 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 0 -4 -7
2018-03-31 0 -4 -6
2017-12-31 0 -4 -5
2017-09-30 0 -5 -5
2017-06-30 0 -6 -5
2017-03-31 0 -7 -8
2016-12-31 0 -9 -11
2016-09-30 0 -10 -13
2016-06-30 0 -12 -16
2016-03-31 0 -13 -16
2015-12-31 0 -13 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NOXXON Pharma is high growth as no earnings estimate data is available.
  • NOXXON Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:0N6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from NOXXON Pharma Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:0N6 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31
2018-12-31
BST:0N6 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -3.12
2018-03-31 -2.84
2017-12-31 -2.54
2017-09-30 -2.55
2017-06-30 -2.64
2017-03-31 -4.51
2016-12-31 -6.71
2016-09-30 -8.29
2016-06-30 -9.82
2016-03-31 -11.79
2015-12-31 -14.77

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NOXXON Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NOXXON Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NOXXON Pharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0N6 Past Performance

  How has NOXXON Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NOXXON Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NOXXON Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare NOXXON Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NOXXON Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NOXXON Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NOXXON Pharma Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:0N6 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.07 -7.21 2.71 2.35
2018-03-31 0.15 -6.30 2.66 2.37
2017-12-31 0.23 -5.39 2.61 2.38
2017-09-30 0.36 -5.10 2.72 2.72
2017-06-30 0.48 -4.96 2.86 3.03
2017-03-31 0.47 -7.85 3.48 3.84
2016-12-31 0.47 -10.75 4.10 4.66
2016-09-30 0.35 -13.46 5.13 5.39
2016-06-30 0.23 -16.18 6.16 6.12
2016-03-31 0.13 -16.14 6.78 6.46
2015-12-31 0.04 -16.10 7.39 6.80
2014-12-31 0.03 -13.80 3.69 9.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NOXXON Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if NOXXON Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NOXXON Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess NOXXON Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NOXXON Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0N6 Health

 How is NOXXON Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NOXXON Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NOXXON Pharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • NOXXON Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NOXXON Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NOXXON Pharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NOXXON Pharma Company Filings, last reported 5 months ago.

BST:0N6 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -4.36 2.78 0.80
2018-03-31 -4.36 2.78 0.80
2017-12-31 -3.92 2.61 0.62
2017-09-30 -3.92 2.61 0.62
2017-06-30 -2.45 1.57 1.12
2017-03-31 -2.45 1.57 1.12
2016-12-31 -2.48 2.94 2.21
2016-09-30 -2.48 2.94 2.21
2016-06-30 -11.78 11.08 1.82
2016-03-31 -11.78 11.08 1.82
2015-12-31 -7.03 8.88 4.09
2014-12-31 -6.24 6.32 1.53
  • NOXXON Pharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if NOXXON Pharma's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NOXXON Pharma has less than a year of cash runway based on current free cash flow.
  • NOXXON Pharma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -55.8% each year.
X
Financial health checks
We assess NOXXON Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NOXXON Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0N6 Dividends

 What is NOXXON Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NOXXON Pharma dividends.
If you bought €2,000 of NOXXON Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NOXXON Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NOXXON Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:0N6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:0N6 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NOXXON Pharma has not reported any payouts.
  • Unable to verify if NOXXON Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NOXXON Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NOXXON Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NOXXON Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NOXXON Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NOXXON Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0N6 Management

 What is the CEO of NOXXON Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aram Mangasarian
COMPENSATION €344,311
AGE 48
TENURE AS CEO 3.4 years
CEO Bio

Dr. Aram Mangasarian has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma AG since July 1, 2015 and served as its has been Chief Business Officer since May 18, 2010 and serves as its Member of Executive Board. Dr. Mangasarian is responsible for corporate and business development activities for NOXXON. He has more than 10 years of business development and strategic planning experience within the biotechnology and pharmaceutical industry. He served as Vice President of Business Development of Novexel SA. Dr. Mangasarian joined Novexel SA group from another French firm, ExonHit Therapeutics SA, a publicly traded French drug discovery and development company, where he spent over five years in business development, most recently as Vice President of Business Development. During this time, Dr. Mangasarian identified strategic partners, negotiated alliances and was responsible for marketing and sales of research products. He led the team that built strategic alliances and negotiated research agreements with a number of pharmaceutical companies. A key part of his role at ExonHit was the development of commercialization strategies. Dr. Mangasarian concluded a number of licensing and research agreements and prepared Novexel SA towards IPO. During his time in the laboratory of Didier Trono, he led two different teams in research projects in virology. He has contributed to several scientific publications including Nature Cell Biology and the Journal of Virology. Prior to ExonHit, he held a postdoctoral fellowship at The University of Geneva Medical School in the Department of Genetics and Microbiology from 1997 to 1999. As graduate of the University of California, San Diego, Dr. Mangasarian earned his PhD in the Department of Biology by conducting research on HIV. He holds an MBA, from Insead.

CEO Compensation
  • Aram's compensation has increased whilst company is loss making.
  • Aram's remuneration is about average for companies of similar size in Germany.
Management Team

Aram Mangasarian

TITLE
CEO & Member of Management Board
COMPENSATION
€344K
AGE
48
TENURE
3.4 yrs

Jarl Jungnelius

TITLE
Chief Medical Officer & Member of Management Board
AGE
67
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the NOXXON Pharma board of directors in years:

2.9
Average Tenure
60
Average Age
  • The average tenure for the NOXXON Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Don deBethizy

TITLE
Chairman of Supervisory Board
COMPENSATION
€11K
AGE
68
TENURE
1.3 yrs

Bertram Köhler

TITLE
Vice Chairman of the Supervisory Board
AGE
46

Hubert Birner

TITLE
Member of Supervisory Board
AGE
52
TENURE
3.5 yrs

Walter Wenninger

TITLE
Member of Supervisory Board
COMPENSATION
€12K
AGE
80
TENURE
2.9 yrs

Jan Burger

TITLE
Member of Nox-A12 Advisory Board

Kai Hübel

TITLE
Member of Nox-A12 Advisory Board

Ibrahim Yakoub-Agha

TITLE
Member of Nox-A12 Advisory Board

Martin Brown

TITLE
Member of Nox-A12 Advisory Board

Wolfgang Wick

TITLE
Member of Nox-A12 Advisory Board

Hans-Joachim Anders

TITLE
Member of Nox-E36 Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NOXXON Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NOXXON Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0N6 News

External News
Loading...
Simply Wall St News

0N6 Company Info

Map
Description

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

Details
Name: NOXXON Pharma N.V.
0N6
Exchange: BST
Founded: 1997
€13,983,435
9,260,553
Website: http://www.noxxon.com
Address: NOXXON Pharma N.V.
Max-Dohrn-Strasse 8-10,
Berlin,
Berlin, 10589,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALNOX Ordinary Shares Euronext Paris FR EUR 30. Sep 2016
DB 0N6 Ordinary Shares Deutsche Boerse AG DE EUR 30. Sep 2016
BST 0N6 Ordinary Shares Boerse-Stuttgart DE EUR 30. Sep 2016
Number of employees
Current staff
Staff numbers
0
NOXXON Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/08 22:38
End of day share price update: 2018/09/10 00:00
Last estimates confirmation: 2018/12/07
Last earnings filing: 2018/10/11
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.